Apimeds Pharmaceuticals US, Inc

AMEX: APUS · Healthcare · Biotechnology

PublicHQ Hopewell, NJ · MercerCIK 0001894525Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 71DQ —GM —SS 23

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$6.0M

Employees

as of 2026-08-26

Market cap

$7.5M

as of 2026-08-26

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$6.0M-$6.0M2025

Operating income-$11.9M-$11.9M2025

Total assets$164.2M$164.2M2025

Liabilities$10.8M$10.8M2025

Equity$153.3M$153.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Apimeds Pharmaceuticals US, Inc’s financial profile?

Apimeds Pharmaceuticals US, Inc earned -$6.0M in FY2025 net income.

Peers · Healthcare

AI Maverick Intel, Inc.——Aprea Therapeutics, Inc.——Univec, Inc.——Liminatus Pharma, Inc. Class A Common Stock——Curative Biotechnology, Inc.——Curanex Pharmaceuticals Inc Common Stock——

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Essential Properties Realty Trust, Inc.$561.2M71B Clearway Energy, Inc.$1.4B54D Miami International Holdings, Inc. $1.4B43D UroGen Pharma Ltd.$109.8M55C Kardigan, Inc.$0——

Key facts

CEOVinod Menon

SectorHealthcare

IndustryBiotechnology

HeadquartersHopewell, NJ

ExchangeAMEX: APUS

Employees7

IPO date2025-05-09

Latest filings

8-K2026-08-21 10-Q2026-08-14 8-K2026-08-06 8-K2026-07-13 10-Q2026-05-26 8-K2026-05-05 8-K2026-05-04 10-K2026-05-04

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.